1. Colon cancer is the second leading cause of cancer death in men and women in Europe1.
The number of cases is expected to increase further over the next 20 years due to the aging of the population. But if diagnosed early enough, colon cancer has a high cure rate and can be prevented by removing adenomatous polyps.
2. More than 90% of patients diagnosed at an early stage can be definitively cured.
Most colon cancers usually develop slowly over several years. Often these are benign precursor lesions called adenomatous polyps. Over time, these benign colon lesions can turn into cancer. Tumors in the early stages (localized and limited to the wall of the colon) can be removed by surgery. More than 90% of patients diagnosed at an early stage can be definitively cured. However, in more advanced stages, the cancer spreads locally and the survival rate drops to 70%. Thereafter, if the cancer becomes metastatic, the survival rate drops to 10%.
3. 50 is the key age
The European Commission3 and the Swiss Cancer League4 recommend regular screening of the medium-risk population from the age of 50 as an essential measure for detection of colon cancer and early intervention. Currently, screening tools recommended in Europe include colonoscopy and tests for stool occult blood.
4. Unfortunately, due to the unpleasant nature of these tests and the fear generated by invasive procedures, compliance with screening is insufficient.
This low compliance results in an unnecessarily high and yet preventable incidence and mortality rate of colon cancer.
5. There is an innovative and effective blood test for the early detection of colorectal cancer: the Colox® test.
Unilabs partners with Novigenix to help patients and the medical community by providing Colox®, an innovative, non-invasive and effective blood test aimed at reducing the incidence and mortality rates of colorectal cancer by early detection of the disease. Click here to find out more.